
CLAIMS

1. An antisense oligomer according to Formula (I):





(I)


or a pharmaceutically acceptable salt thereof, wherein:

each **Nu** is a nucleobase which taken together form a targeting sequence;

T' in Formula (I) is a moiety selected from:



;


; and


;

R[100] and **R**[200] are each independently hydrogen or a cell-penetrating peptide and **R**[1] is C_1-C_6 alkyl;

each **Nu** from 1 to (**n**+1) and 5' to 3' corresponds to the nucleobases in one of the following:

Annealing Site	**Base Sequence [5' to 3']**	**SEQ ID NO.**
H2.SA.(-20+05)	TTC ATC TAA AAT GCA AAA TAA AAA A	SEQ ID NO. 1
H2.SA.(-14+11)	TTC TCT TTC ATC TAA AAT GCA AAA T	SEQ ID NO. 2
H2.SA.(-11+14)	ATC TTC TCT TTC ATC TAA AAT GCA A	SEQ ID NO. 3
H2.SA.(-08+17)	AAC ATC TTC TCT TTC ATC TAA AAT G	SEQ ID NO. 4
H2.SA.(-05+20)	TTG AAC ATC TTC TCT TTC ATC TAA A	SEQ ID NO. 5
H2A(-38-14)	TAA AAA AAT AAA AGT TAG GAA GCA A	SEQ ID NO. 34
H2A(-41-17)	AAA AAT AAA AGT TAG GAA GCA ACT T	SEQ ID NO. 35

wherein T is thymine or uracil.

2. The antisense oligomer of claim 1, or a pharmaceutically acceptable salt thereof, wherein each **Nu** from 1 to (**n**+1) and 5' to 3' of Formula (I) corresponds to the nucleobases in one of the following:


Annealing Site	**Base Sequence [5' to 3']**	**SEQ ID NO.**
H2.SA.(-20+05)	TTC ATC TAA AAT GCA AAA TAA AAA A	SEQ ID NO. 1
H2.SA.(-14+11)	TTC TCT TTC ATC TAA AAT GCA AAA T	SEQ ID NO. 2
H2.SA.(-11+14)	ATC TTC TCT TTC ATC TAA AAT GCA A	SEQ ID NO. 3
H2.SA.(-08+17)	AAC ATC TTC TCT TTC ATC TAA AAT G	SEQ ID NO. 4
H2.SA.(-05+20)	TTG AAC ATC TTC TCT TTC ATC TAA A	SEQ ID NO. 5
H2A(-38-14)	TAA AAA AAT AAA AGT TAG GAA GCA A	SEQ ID NO. 34
H2A(-41-17)	AAA AAT AAA AGT TAG GAA GCA ACT T	SEQ ID NO. 35

3. The antisense oligomer of claim 1, wherein each **Nu** from 1 to (**n**+1) and 5' to 3' of Formula (I) corresponds to one of the following: SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 35.

4. The antisense oligomer of claim 1, wherein each **Nu** from 1 to (**n**+1) and 5' to 3' of Formula (I) corresponds to one of the following: SEQ ID NO. 3 or SEQ ID NO. 5.

5. The antisense oligomer of any one of claims 1-4, wherein T is thymine.

6. The antisense oligomer of claim 5, wherein:

T' is 

.